Home   >  
Neuro Signaling Pathway
  • GPCR/G Protein
  >  
Adrenergic Receptor
  >   Alfuzosin hydrochloride
Alfuzosin hydrochloride Chemical Structure

Alfuzosin hydrochloride

Data Sheet For research use only. Not for human use.
Cat. No. :BCP02086CAS No. :81403-68-1Purity:98%
 Tel: 0086-13026320035   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 81403-68-1 Cat. No. BCP02086
Name Alfuzosin hydrochloride
Synonyms Uroxatral;
SMILES
Chemical Name
Formula C19H27N5O4.HCl M. Wt 425.91
Purity 98% Storage Store at 4-8°C
Description Alfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder outlet resistance, bladder instability and symptoms associated with benign prostatic hyperplasia are reduced. A limited range of clinical studies have shown oral alfuzosin to be more effective than placebo (in studies of < or = 6 months duration), to have sustained effects on long term administration (< or = 30 months), and to be comparable with the alpha 1-adrenoceptor antagonist prazosin, in the symptomatic treatment of benign prostatic hyperplasia. Oral alfuzosin 7.5 to 10 mg/day in divided doses appears to be a promising first-line agent for symptomatic treatment of noncomplicated mild to moderate benign prostatic hyperplasia in patients with a high dynamic component t
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Alfuzosin hydrochloride supplier,Alfuzosin hydrochloride purchase,Alfuzosin hydrochloride manufacturer,Alfuzosin hydrochloride distributor,Alfuzosin hydrochloride cost,Alfuzosin hydrochloride buy,Alfuzosin hydrochloride for sale

0086-13720134139